Please Wait.....
Report
Ibuprofen Market By Type (Tablet, Capsule, Syrup, Injection, Others) , By Application (Rheumatoid Arthritis and Osteoarthritis, Cancer, Pain/Fever/Dysmenorrhea, Inflammatory Diseases, Headache, Others) By Distribution Channel (Hospital pharmacies, Retail Pharmacies, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 280 Pages I Allied Market Research
Ibuprofen Market
The ibuprofen market was valued at $100.0 million in 2023 and is projected to reach $213.6 million by 2033, growing at a CAGR of 7.9% from 2024 to 2033.
Ibuprofen is a nonsteroidal anti-inflammatory drugpopular for its efficacy in alleviating pain, reducing inflammation, and lowering fever. It belongs to the analgesics class of medications which areused to ease mild to moderate pain, such as headaches, muscle aches, toothaches,menstrual cramps, and arthritis. The action mechanism of the medication involves inhibiting the production of prostaglandins inside the body, compounds that are the cause of pain and inflammation.
The versatility of ibuprofen in treating several health conditions is a key driver of the market. In addition, ibuprofen witnesses a high demand in several countries where it is accessible as over-the-counter medication, hence contributing to self-medication and elevating the convenience of customers. The market is currently witnessing an emerging trend of de-fossilization of pharmaceuticals. The typical source of formation of ibuprofen is from crude oils. Researchers at the University of Bath have recently discovered a method to develop the medication out of waste generated from the paper manufacturing industry. This discovery marks a significant step by the pharmaceuticals industry toward sustainability.
Despite its benefits, long-term usage of ibuprofen is known to cause severe side-effects such as cardiovascular risks, gastrointestinal complications, and kidney damage. These factors deter several individuals from the consumption of medication, hence restraining the market growth. According to a study posted by the British Medical Journal, ibuprofen is anticipated to elevate the risk of cardiac arrests by 31%. In a similar way, a study published in the Proceedings of the National Academy of Sciences states that high uptake of ibuprofen in young healthymen results in less production of reproductive hormones and occurrenceof compensated hypogonadism disorder.
Segment Review
The ibuprofen market is segmented into type, application, distribution channel, and region. On the basis of type, the market is divided into tablet, capsule, syrup, injection, and others. As per application, it is classified into rheumatoid arthritis & osteoarthritis, cancer, pain/fever/dysmenorrhea, inflammatory diseases, headache, and others. Depending on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of type, the tablet segment dominated the market share in 2023.
As per application, the rheumatoid arthritis segment generated the highest revenue in 2023.
Depending on distribution channel, the hospital pharmacies segment acquired a high market share in 2023.
Region wise, North America is expected to dominate the market by 2033.
Competition Analysis
The major players operating in theglobal ibuprofen market includePfizer Inc., Abbott Laboratories Ltd., Solara Active Pharma Sciences Ltd., ?h?nd?ng ??nhu? ?h?rm???ut???l ??.Ltd, ??L ?h?m???l? and ?h?rm???ut???l L?m?t?d, ?ub?? ?????u?? ?h?rm???ut???l ??.Ltd, ?tr?d?? ?h?rm? ????n?? L?m?t?d (?h??un ?h?rm???ut???l? L?m?t?d), ??rr?g? ??m??n? ?l?, BASF SE, and Biocause Inc.These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Type
- Tablet
- Capsule
- Syrup
- Injection
- Others
By Application
- Rheumatoid Arthritis and Osteoarthritis
- Cancer
- Pain/Fever/Dysmenorrhea
- Inflammatory Diseases
- Headache
- Others
By Distribution Channel
- Hospital pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Pfizer Inc.
- Abbott Laboratories
- Solara Active Pharma Sciences Ltd
- BASF SE
- Biocause Inc
- Shandong Xinhua Pharmaceutical Co Ltd
- IOL Chemicals and Pharmaceutical Ltd
- Hubei Biocause Pharmaceutical Co Ltd
- Strides Pharma Science Ltd
- Perrigo Company Plc
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: FOLLICLE STIMULATING HORMONE MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Recombinant FSH
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Urinary FSH
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Infertility Treatment
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Assisted Reproductive Technology
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: FOLLICLE STIMULATING HORMONE MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Hospitals
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Fertility Clinics
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Cryobanks
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: FOLLICLE STIMULATING HORMONE MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Type
7.2.3. Market Size and Forecast, By Application
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Follicle Stimulating Hormone Market
7.2.6.1. Market Size and Forecast, By Type
7.2.6.2. Market Size and Forecast, By Application
7.2.6.3. Market Size and Forecast, By End User
7.2.7. Canada Follicle Stimulating Hormone Market
7.2.7.1. Market Size and Forecast, By Type
7.2.7.2. Market Size and Forecast, By Application
7.2.7.3. Market Size and Forecast, By End User
7.2.8. Mexico Follicle Stimulating Hormone Market
7.2.8.1. Market Size and Forecast, By Type
7.2.8.2. Market Size and Forecast, By Application
7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Type
7.3.3. Market Size and Forecast, By Application
7.3.4. Market Size and Forecast, By End User
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Follicle Stimulating Hormone Market
7.3.6.1. Market Size and Forecast, By Type
7.3.6.2. Market Size and Forecast, By Application
7.3.6.3. Market Size and Forecast, By End User
7.3.7. France Follicle Stimulating Hormone Market
7.3.7.1. Market Size and Forecast, By Type
7.3.7.2. Market Size and Forecast, By Application
7.3.7.3. Market Size and Forecast, By End User
7.3.8. UK Follicle Stimulating Hormone Market
7.3.8.1. Market Size and Forecast, By Type
7.3.8.2. Market Size and Forecast, By Application
7.3.8.3. Market Size and Forecast, By End User
7.3.9. Italy Follicle Stimulating Hormone Market
7.3.9.1. Market Size and Forecast, By Type
7.3.9.2. Market Size and Forecast, By Application
7.3.9.3. Market Size and Forecast, By End User
7.3.10. Spain Follicle Stimulating Hormone Market
7.3.10.1. Market Size and Forecast, By Type
7.3.10.2. Market Size and Forecast, By Application
7.3.10.3. Market Size and Forecast, By End User
7.3.11. Rest of Europe Follicle Stimulating Hormone Market
7.3.11.1. Market Size and Forecast, By Type
7.3.11.2. Market Size and Forecast, By Application
7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Type
7.4.3. Market Size and Forecast, By Application
7.4.4. Market Size and Forecast, By End User
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Follicle Stimulating Hormone Market
7.4.6.1. Market Size and Forecast, By Type
7.4.6.2. Market Size and Forecast, By Application
7.4.6.3. Market Size and Forecast, By End User
7.4.7. China Follicle Stimulating Hormone Market
7.4.7.1. Market Size and Forecast, By Type
7.4.7.2. Market Size and Forecast, By Application
7.4.7.3. Market Size and Forecast, By End User
7.4.8. Australia Follicle Stimulating Hormone Market
7.4.8.1. Market Size and Forecast, By Type
7.4.8.2. Market Size and Forecast, By Application
7.4.8.3. Market Size and Forecast, By End User
7.4.9. India Follicle Stimulating Hormone Market
7.4.9.1. Market Size and Forecast, By Type
7.4.9.2. Market Size and Forecast, By Application
7.4.9.3. Market Size and Forecast, By End User
7.4.10. South Korea Follicle Stimulating Hormone Market
7.4.10.1. Market Size and Forecast, By Type
7.4.10.2. Market Size and Forecast, By Application
7.4.10.3. Market Size and Forecast, By End User
7.4.11. Rest of Asia-Pacific Follicle Stimulating Hormone Market
7.4.11.1. Market Size and Forecast, By Type
7.4.11.2. Market Size and Forecast, By Application
7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Type
7.5.3. Market Size and Forecast, By Application
7.5.4. Market Size and Forecast, By End User
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Follicle Stimulating Hormone Market
7.5.6.1. Market Size and Forecast, By Type
7.5.6.2. Market Size and Forecast, By Application
7.5.6.3. Market Size and Forecast, By End User
7.5.7. Saudi Arabia Follicle Stimulating Hormone Market
7.5.7.1. Market Size and Forecast, By Type
7.5.7.2. Market Size and Forecast, By Application
7.5.7.3. Market Size and Forecast, By End User
7.5.8. South Africa Follicle Stimulating Hormone Market
7.5.8.1. Market Size and Forecast, By Type
7.5.8.2. Market Size and Forecast, By Application
7.5.8.3. Market Size and Forecast, By End User
7.5.9. Rest of LAMEA Follicle Stimulating Hormone Market
7.5.9.1. Market Size and Forecast, By Type
7.5.9.2. Market Size and Forecast, By Application
7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Novartis AG
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Abbott Laboratories
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Sanofi S.A.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Boehringer Ingelheim GmbH
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Merck KGaA
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Teva Pharmaceutical Industries Ltd.
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Intas Pharmaceuticals Ltd.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Cipla Ltd.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Zydus Lifesciences Limited
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 2. IBUPROFEN MARKET FOR TABLET, BY REGION, 2024 - 2033 ($MILLION)
TABLE 3. IBUPROFEN MARKET FOR CAPSULE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 4. IBUPROFEN MARKET FOR SYRUP, BY REGION, 2024 - 2033 ($MILLION)
TABLE 5. IBUPROFEN MARKET FOR INJECTION, BY REGION, 2024 - 2033 ($MILLION)
TABLE 6. IBUPROFEN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 7. GLOBAL IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 8. IBUPROFEN MARKET FOR RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 9. IBUPROFEN MARKET FOR CANCER, BY REGION, 2024 - 2033 ($MILLION)
TABLE 10. IBUPROFEN MARKET FOR PAIN/FEVER/DYSMENORRHEA, BY REGION, 2024 - 2033 ($MILLION)
TABLE 11. IBUPROFEN MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 12. IBUPROFEN MARKET FOR HEADACHE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 13. IBUPROFEN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 14. GLOBAL IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 15. IBUPROFEN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 16. IBUPROFEN MARKET FOR RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 17. IBUPROFEN MARKET FOR ONLINE PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 18. IBUPROFEN MARKET, BY REGION, 2024 - 2033 ($MILLION)
TABLE 19. NORTH AMERICA IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 20. NORTH AMERICA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 21. NORTH AMERICA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 22. NORTH AMERICA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 23. U.S. IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 24. U.S. IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 25. U.S. IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 26. CANADA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 27. CANADA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 28. CANADA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 29. MEXICO IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 30. MEXICO IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 31. MEXICO IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 32. EUROPE IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 33. EUROPE IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 34. EUROPE IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 35. EUROPE IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 36. GERMANY IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 37. GERMANY IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 38. GERMANY IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 39. FRANCE IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 40. FRANCE IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 41. FRANCE IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 42. UK IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 43. UK IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 44. UK IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 45. ITALY IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 46. ITALY IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 47. ITALY IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 48. SPAIN IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 49. SPAIN IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 50. SPAIN IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 51. REST OF EUROPE IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 52. REST OF EUROPE IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 53. REST OF EUROPE IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 54. ASIA-PACIFIC IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 55. ASIA-PACIFIC IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 56. ASIA-PACIFIC IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 57. ASIA-PACIFIC IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 58. JAPAN IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 59. JAPAN IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 60. JAPAN IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 61. CHINA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 62. CHINA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 63. CHINA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 64. AUSTRALIA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 65. AUSTRALIA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 66. AUSTRALIA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 67. INDIA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 68. INDIA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 69. INDIA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 70. SOUTH KOREA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 71. SOUTH KOREA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 72. SOUTH KOREA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 76. LAMEA IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 77. LAMEA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 78. LAMEA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 79. LAMEA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 80. BRAZIL IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 81. BRAZIL IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 82. BRAZIL IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 83. SAUDI ARABIA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 84. SAUDI ARABIA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 85. SAUDI ARABIA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 86. SOUTH AFRICA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 87. SOUTH AFRICA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 88. SOUTH AFRICA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 89. REST OF LAMEA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 90. REST OF LAMEA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 91. REST OF LAMEA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 92. PFIZER INC.: KEY EXECUTIVES
TABLE 93. PFIZER INC.: COMPANY SNAPSHOT
TABLE 94. PFIZER INC.: OPERATING SEGMENTS
TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 96. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 98. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 99. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 100. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 101. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. SOLARA ACTIVE PHARMA SCIENCES LTD: KEY EXECUTIVES
TABLE 103. SOLARA ACTIVE PHARMA SCIENCES LTD: COMPANY SNAPSHOT
TABLE 104. SOLARA ACTIVE PHARMA SCIENCES LTD: OPERATING SEGMENTS
TABLE 105. SOLARA ACTIVE PHARMA SCIENCES LTD: PRODUCT PORTFOLIO
TABLE 106. SOLARA ACTIVE PHARMA SCIENCES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. BASF SE: KEY EXECUTIVES
TABLE 108. BASF SE: COMPANY SNAPSHOT
TABLE 109. BASF SE: OPERATING SEGMENTS
TABLE 110. BASF SE: PRODUCT PORTFOLIO
TABLE 111. BASF SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. BIOCAUSE INC: KEY EXECUTIVES
TABLE 113. BIOCAUSE INC: COMPANY SNAPSHOT
TABLE 114. BIOCAUSE INC: OPERATING SEGMENTS
TABLE 115. BIOCAUSE INC: PRODUCT PORTFOLIO
TABLE 116. BIOCAUSE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. SHANDONG XINHUA PHARMACEUTICAL CO LTD: KEY EXECUTIVES
TABLE 118. SHANDONG XINHUA PHARMACEUTICAL CO LTD: COMPANY SNAPSHOT
TABLE 119. SHANDONG XINHUA PHARMACEUTICAL CO LTD: OPERATING SEGMENTS
TABLE 120. SHANDONG XINHUA PHARMACEUTICAL CO LTD: PRODUCT PORTFOLIO
TABLE 121. SHANDONG XINHUA PHARMACEUTICAL CO LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122. IOL CHEMICALS AND PHARMACEUTICAL LTD: KEY EXECUTIVES
TABLE 123. IOL CHEMICALS AND PHARMACEUTICAL LTD: COMPANY SNAPSHOT
TABLE 124. IOL CHEMICALS AND PHARMACEUTICAL LTD: OPERATING SEGMENTS
TABLE 125. IOL CHEMICALS AND PHARMACEUTICAL LTD: PRODUCT PORTFOLIO
TABLE 126. IOL CHEMICALS AND PHARMACEUTICAL LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: KEY EXECUTIVES
TABLE 128. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: COMPANY SNAPSHOT
TABLE 129. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: OPERATING SEGMENTS
TABLE 130. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: PRODUCT PORTFOLIO
TABLE 131. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132. STRIDES PHARMA SCIENCE LTD: KEY EXECUTIVES
TABLE 133. STRIDES PHARMA SCIENCE LTD: COMPANY SNAPSHOT
TABLE 134. STRIDES PHARMA SCIENCE LTD: OPERATING SEGMENTS
TABLE 135. STRIDES PHARMA SCIENCE LTD: PRODUCT PORTFOLIO
TABLE 136. STRIDES PHARMA SCIENCE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 137. PERRIGO COMPANY PLC: KEY EXECUTIVES
TABLE 138. PERRIGO COMPANY PLC: COMPANY SNAPSHOT
TABLE 139. PERRIGO COMPANY PLC: OPERATING SEGMENTS
TABLE 140. PERRIGO COMPANY PLC: PRODUCT PORTFOLIO
TABLE 141. PERRIGO COMPANY PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL IBUPROFEN MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF IBUPROFEN MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN IBUPROFEN MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIBUPROFEN MARKET
FIGURE 10. GLOBAL IBUPROFEN MARKET SEGMENTATION, BY TYPE
FIGURE 11. IBUPROFEN MARKET FOR TABLET, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 12. IBUPROFEN MARKET FOR CAPSULE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 13. IBUPROFEN MARKET FOR SYRUP, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 14. IBUPROFEN MARKET FOR INJECTION, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 15. IBUPROFEN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 16. GLOBAL IBUPROFEN MARKET SEGMENTATION, BY APPLICATION
FIGURE 17. IBUPROFEN MARKET FOR RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 18. IBUPROFEN MARKET FOR CANCER, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 19. IBUPROFEN MARKET FOR PAIN/FEVER/DYSMENORRHEA, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 20. IBUPROFEN MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 21. IBUPROFEN MARKET FOR HEADACHE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 22. IBUPROFEN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 23. GLOBAL IBUPROFEN MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
FIGURE 24. IBUPROFEN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 25. IBUPROFEN MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 26. IBUPROFEN MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 31. COMPETITIVE DASHBOARD
FIGURE 32. COMPETITIVE HEATMAP: IBUPROFEN MARKET
FIGURE 33. TOP PLAYER POSITIONING, 2023
FIGURE 34. PFIZER INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 35. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 36. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 37. ABBOTT LABORATORIES: NET SALES, 2021-2023 ($MILLION)
FIGURE 38. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 39. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 40. SOLARA ACTIVE PHARMA SCIENCES LTD: NET SALES, 2021-2023 ($MILLION)
FIGURE 41. SOLARA ACTIVE PHARMA SCIENCES LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 42. SOLARA ACTIVE PHARMA SCIENCES LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 43. BASF SE: NET SALES, 2021-2023 ($MILLION)
FIGURE 44. BASF SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 45. BASF SE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 46. BIOCAUSE INC: NET SALES, 2021-2023 ($MILLION)
FIGURE 47. BIOCAUSE INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 48. BIOCAUSE INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 49. SHANDONG XINHUA PHARMACEUTICAL CO LTD: NET SALES, 2021-2023 ($MILLION)
FIGURE 50. SHANDONG XINHUA PHARMACEUTICAL CO LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 51. SHANDONG XINHUA PHARMACEUTICAL CO LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 52. IOL CHEMICALS AND PHARMACEUTICAL LTD: NET SALES, 2021-2023 ($MILLION)
FIGURE 53. IOL CHEMICALS AND PHARMACEUTICAL LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 54. IOL CHEMICALS AND PHARMACEUTICAL LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 55. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: NET SALES, 2021-2023 ($MILLION)
FIGURE 56. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 57. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 58. STRIDES PHARMA SCIENCE LTD: NET SALES, 2021-2023 ($MILLION)
FIGURE 59. STRIDES PHARMA SCIENCE LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 60. STRIDES PHARMA SCIENCE LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 61. PERRIGO COMPANY PLC: NET SALES, 2021-2023 ($MILLION)
FIGURE 62. PERRIGO COMPANY PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 63. PERRIGO COMPANY PLC: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security